NextPoint Therapeutics Funding & Investors
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.
nextpointtx.comTotal Amount Raised: $122,500,000
NextPoint Therapeutics Funding Rounds
Series B
$42,500,000
Series B Investors
Catalio Capital ManagementMPM CapitalSanofi VenturesSixty Degree CapitalBinney Street CapitalWTT InvestmentGordon FreemanArkin HoldingsInvusLeaps by BayerSeries B
$80,000,000
Series B Investors
Leaps by BayerSanofi VenturesPagodaTree PartnersGordon FreemanSixty Degree CapitalMPM CapitalInvusBinney Street CapitalCatalio Capital Management
Funding info provided by Diffbot.